Eleven Biotherapeutics (EBIO) Initiates Pivotal Phase 3 Clinical Study With EBI-005 In Dry Eye Disease
2/18/2014 10:00:07 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company’s first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease). EBI-005, the Company’s most advanced product candidate generated using its AMP-Rx platform, is a novel, topically administered Interleukin-1 (IL-1) receptor blocker currently in development for the treatment of dry eye disease and allergic conjunctivitis. EBI-005 was designed to bind and block the IL-1 receptor to prevent transmission of biological signals responsible for many of the signs and symptoms of ocular surface diseases.
Help employers find you! Check out all the jobs and post your resume.
comments powered by